This phenomenon seems to be very striking, Rab22a-NeoF1 fusion protein may be limited in its negative recipient cancer cells as it is taken up by exosome endocytosis, and then it binds to PYK2 kinase that has a high efficiency to activate RhoA. The gene discussed is RAB22A; the disease is cancer.